Sonus' EchoGen still not approvable in US
This article was originally published in Clinica
Executive Summary
The US FDA has told ultrasound contrast agent developer Sonus Pharmaceuticals that its first product, EchoGen, is still not approvable, despite the additional data submitted by the company after its first application was rejected in 1998.